Search

Displaying results 1421 - 1430 of 4539 in total
  1. Drug

    Paliperidone

    go.drugbank.com/drugs/DB01267
    ApprovedInvestigational

    The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. … Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.

  2. Drug

    Pantothenic acid

    go.drugbank.com/drugs/DB01783
    ApprovedInvestigationalNutraceuticalVet approved

    Pantothenic acid, also called pantothenate or vitamin B5 (a B vitamin), is a water-soluble vitamin discovered by Roger J. Williams in 1919.

    Mixtures: Pnv-VP-U, Z-FULL MK TABLETAS
  3. Drug

    Sevoflurane

    go.drugbank.com/drugs/DB01236
    ApprovedInvestigationalVet approved

    [A249885] Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. … [L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996.

  4. Drug

    Cefprozil

    go.drugbank.com/drugs/DB01150
    ApprovedInvestigational

    Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.

  5. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

  6. Drug

    Hypromellose

    go.drugbank.com/drugs/DB11075
    ApprovedInvestigational

    Hypromellose, or hydroxypropyl methylcellulose (HPMC) , is a semisynthetic, inert, and viscoelastic polymer that forms a colloid solution when dissolved in water. It acts as a thickening agent, coating polymer, bioadhesive, solubility en...

    Mixtures: SK Dry Eye Relief, SK Dry Eye Relief
  7. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    [L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune

  8. Drug

    Telavancin

    go.drugbank.com/drugs/DB06402
    ApprovedInvestigational

    Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospita...

  9. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    In the US, chlormadinone acetate was formerly marketed as a component of the combination drug products Estalor-21 and C-Quens.

  10. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain